Project 466972

Newer targeted cancer therapies, including epidermal growth factor receptor inhibitors, have fewer systemic side effects than older chemotherapy but cause a near-universal acneiform rash. This rash looks very similar to acne - it is pimples and red bumps on the face, neck and back. In contrast to acne, this rash appears suddenly and can be associated with significant pain and itch. Given it presents on visible areas of the body, the rash can negatively affect quality of life; it is a constant reminder of the challenges encountered by a cancer patient and is visible to others. When the rash resolves, it can cause scarring or changes in the colour of the natural skin's pigment (darkening or lightening). This acneiform rash is a sign that the cancer therapy is working. In some patients, however, the rash may be so severe that the lifesaving cancer therapy must be stopped. Evidence demonstrates that early intervention by a dermatologist to treat the rash can decrease the rate of cancer treatment discontinuation. Therefore, the goal of our research is to identify risk factors for those who develop severe acneiform rashes. The results of our research will be used by oncologists to identify patients at risk of developing these severe rashes, so they are started on treatment earlier by dermatologists. Ultimately, our aim is that this prevents early cancer treatment discontinuation due to a skin side effect. Treatment of this rash will also improve the quality of life of patients undergoing cancer therapy.